New pill aims to ease Parkinson's motor symptoms when added to standard therapy

NCT ID NCT07647614

Not yet recruiting Disease control Sponsor: Energenesis Biomedical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether ENERGI-F705 tablets, taken twice daily alongside standard Parkinson's medications, can improve motor function and safety in people aged 40–75 with idiopathic Parkinson's disease. Participants are randomly assigned to receive a high dose, low dose, or placebo for 72 weeks. The study measures side effects and changes in movement using a standard rating scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ENERGI-F705 tablets
What this could lead to: If successful, this could provide a new add-on treatment option to help control motor symptoms in people with Parkinson's disease.
What could go wrong: This is an early phase 2 trial with only 105 participants, so results may not apply to everyone. The drug may cause side effects or fail to show benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE (PD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON'S DISEASE (PD)

Contacts and locations

Locations

Department of Neurology, Shuang Ho Hospital

New Taipei City, Taiwan
Taipei Medical University Hospital

Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.